financetom
Business
financetom
/
Business
/
US will not enforce Biden wheelchair passenger protection rule
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US will not enforce Biden wheelchair passenger protection rule
Sep 29, 2025 10:15 AM

WASHINGTON, Sept 29 (Reuters) - The U.S. Transportation

Department said on Monday that it will not enforce key

provisions of a rule issued in December by former President Joe

Biden's administration that requires new consumer protections

for disabled passengers using wheelchairs.

United Airlines, Delta Air Lines ( DAL ), American

Airlines ( AAL ), Southwest Airlines ( LUV ), JetBlue Airways ( JBLU )

and airline trade group Airlines for America filed suit

in February challenging the rule that set stricter standards for

accommodating passengers with wheelchairs. The rule also

requires carriers to reimburse passengers for damage to

wheelchairs.

USDOT said in a filing it is writing a new rule and will not

enforce the requirements imposing airline liability for

mishandled wheelchairs or a requirement for airlines to

reimburse passengers using wheelchairs the difference between a

fare on a flight taken and the fare the passenger would have

paid on a flight if their wheelchair could have fit in the cabin

or cargo compartment of a different aircraft.

President Donald Trump's administration also will not

enforce a requirement airlines notify passengers about their

rights in writing when they are checking wheelchairs or

scooters.

Last year, USDOT said an estimated 5.5 million Americans

use a wheelchair and data shows that for every 100 wheelchairs

or scooters transported on domestic flights at least one is

damaged, delayed, or lost.

A spokesman for Transportation Secretary Sean Duffy said

the department has and will continue to support flyers with

disabilities and will enforce other provisions of the rule,

adding the department is reevaluating whether those provisions

"adhere to statute or if they are redundant. No final decision

has been made."

In October 2024, USDOT fined American Airlines ( AAL ) a record $50

million for its treatment of disabled passengers, including

failing to provide some with adequate assistance and mishandling

wheelchairs.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--SEC Bows Out of Fight to Restore Hedge Fund Fee Disclosure Rule, Bloomberg Reports
--SEC Bows Out of Fight to Restore Hedge Fund Fee Disclosure Rule, Bloomberg Reports
Sep 6, 2024
12:06 PM EDT, 09/04/2024 (MT Newswires) -- Price: 108.13, Change: +0.13, Percent Change: +0.12 ...
Tenon Medical to Effect 1-for-8 Reverse Stock Split; Shares Fall
Tenon Medical to Effect 1-for-8 Reverse Stock Split; Shares Fall
Sep 6, 2024
12:03 PM EDT, 09/04/2024 (MT Newswires) -- Tenon Medical ( TNON ) said Wednesday it will implement a 1-for-8 reverse split of its common shares mainly to increase its per-share market price to meet the Nasdaq Capital Market's $1 minimum closing price requirement for continued listing. The company's shares are expected to start trading on a split-adjusted basis Friday. Tenon...
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?
Sep 6, 2024
Atara Biotherapeutics Inc ( ATRA ) shares are trading higher by 30.7% to $8.87 Wednesday morning. The company announced a $36 million registered direct offering of 758,900 shares at $8.25 per share. The offering, priced at a 15% premium to the company’s recent average stock price, involves the sale of 758,900 shares at $8.25 per share and 3,604,780 pre-funded warrants...
What's Going On With Windtree Therapeutics Stock Wednesday?
What's Going On With Windtree Therapeutics Stock Wednesday?
Sep 6, 2024
Windtree Therapeutics, Inc. shares are trading higher Wednesday after the company completed enrollment of its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The Details: The company is hoping to build on the positive results from a previous study, the SEISMiC Phase 2 clinical study, regarding the ability of istaroxime to improve heart...
Copyright 2023-2026 - www.financetom.com All Rights Reserved